What is Allena Pharmaceuticals, Inc. (ALNAQ)?

Allena Pharmaceuticals, Inc. (ALNAQ) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ALNAQ?

The current price of ALNAQ is $0.00. Prices are updated in real time on Stocks360.

What is ALNAQ's price-to-earnings (PE) ratio?

ALNAQ's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is ALNAQ's market capitalization?

ALNAQ's market capitalization is $122.00, placing it in the small-cap tier.

Allena Pharmaceuticals, Inc. (ALNAQ)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$122.00

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-14.54

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $0.02

Avg Volume

N/A

Volume

16.45K

Allena Pharmaceuticals, Inc. (ALNAQ) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $122.00. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 15, 2022

EPS $-0.08 vs est. $-0.07

Missed by $0.01

Proprietary Signals

Signal snapshot temporarily unavailable.

About Allena Pharmaceuticals, Inc.

Operating as a biopharmaceutical firm, Allena Pharmaceuticals, Inc. focuses on unearthing, developing, and marketing oral enzyme therapies. These treatments are devised to assist patients in the United States afflicted by uncommon and serious metabolic as well as renal conditions. Central to its pipeline is ALLN-346, an innovative enzyme designed to degrade urate, targeting hyperuricemia and gout in individuals with advanced chronic kidney disease. The company, which commenced operations in 2011 and has its main office in Newton, Massachusetts, made headlines on September 2, 2022, by seeking voluntary reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	0.00×
P/B	0.00×
P/FCF (TTM)	-0.00×
EV / EBITDA	0.41×
EV / Sales	0.00×
Earnings Yield	-73045000.00%
Free Cash Flow Yield	-37987704.92%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$19.61M
Net Income (TTM)	-$89.11M
Free Cash Flow (TTM)	-$46.34M
Net Debt	-$19.61M
Working Capital	$17.33M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-239.59%
Return on Invested Capital	-162.92%